This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Home Therapy With VPRIV in Gaucher's Disease

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Shire
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01356537
First received: May 17, 2011
Last updated: February 1, 2017
Last verified: February 2017
  Purpose
The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.

Condition
Gaucher Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non Interventional Study of VPRIV® (Velaglucerase Alfa) Home Therapy in Patients With Gaucher's Disease

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Patient satisfaction estimated on a 10-ary Likert scale, quality of life estimated by SF-36 questionnaire [ Time Frame: comparison of baseline to 12 months value ]

Secondary Outcome Measures:
  • Number (per infusion) and severity of infusion-related side effects [ Time Frame: baseline compared to 12 months ]

Estimated Enrollment: 50
Study Start Date: April 2011
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
Gaucher's Disease under VPRIV

  Eligibility

Ages Eligible for Study:   2 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with proven Gaucher's Disease foreseen for home treatment with VPRIV (Velaglucerase alfa) at German Gaucher centers
Criteria

Inclusion Criteria:

  • Male or female patients with a confirmed diagnosis of Gaucher disease type 1
  • Age> 2 years
  • patients who have at least 3 infusions (6 weeks) at least 5-year or 5-6 infusions (10-12 weeks) at 2 - to 4-year patients have received VPRIV ® and tolerate well
  • The patient is compliant, the previous VPRIV ® infusions were / performed approximately every 2 weeks in the center during office visits
  • The patient was already before inclusion in this study for a home infusion therapy and has consented to (or their legal representative)
  • The patient / be lawful. Representative has consented in writing to participate in this study.

Exclusion criteria:

• The patient is participating in a clinical trial with a medicinal product

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01356537

Contacts
Contact: Shire Contact clinicaltransparency@shire.com

Locations
Austria
Landeskrankenhaus Bregenz Recruiting
Bregenz, Austria, A-6900
Contact: Martina Huemer, MD    +43 (0)5574 401-6507    Martina.Huemer@lkhb.at   
Principal Investigator: Martina Huemer, MD         
Principal Investigator: Yildiz Yildiz, MD         
Paracelsus Medizinische Privatuniversität Salzburg Recruiting
Salzburg, Austria, A-5020
Contact: Florian B. Lagler, MD    43 662 442002 1224    florian.lagler@pmu.ac.at   
Principal Investigator: Florian B. Lagler, MD         
AKH, Allgemeines Krankenhaus der Stadt Wien Recruiting
Wien, Austria, A-1090
Contact: Dorothea Möslinger, MD    +43-1-40400-3232    Dorothea.Moeslinger@meduniwien.ac.at   
Principal Investigator: Vassiliki Konstantopoulou, MD         
Medical University of Vienna Recruiting
Wien, Austria, A-1090
Contact: Thomas Stulnig, MD    +43 (0)1 40400 4368    thomas.stulnig@meduniwien.ac.at   
Principal Investigator: Thomas Stulnig, MD         
Medizinische Universität Wien Recruiting
Wien, Austria, A-1090
Contact: Prof. Thomas Stulnig, MD    +43 1 40400 4368    thomas.stulnig@meduniwien.ac.at   
Principal Investigator: Thomas Stulnig, MD         
Germany
Endocrinology in the center Withdrawn
Erlangen, Germany, D-91054
Facharzt für Chirurgie und Orthopädie Withdrawn
Hamburg, Germany, D-22607
Gastroenterological FOCUS PRACTICE Dr. med. Hans Werner Karch Withdrawn
Kirn, Germany, 55606
Gemeinschaftspraxis für Hämatologie und Onkologie Recruiting
Köln, Germany, 51103
Contact: Tatjana Gruner-Ewald    +49 221 989 44717    bod.t.gruner@gmail.com   
Principal Investigator: Achim Rothe, MD         
Universitätsklinikum Mainz Recruiting
Mainz, Germany, 55131
Contact: Eugen Mengel, Dr.    +49 6131 172781    mengel@kinder.klinik.uni-mainz.de   
Principal Investigator: Eugen Mengel, MD         
Group Practice, Drs Klaus Michels and Michels Alexander Withdrawn
Mühlhausen, Germany, D-92360
Klinikum rechts der Isar Recruiting
München, Germany, D-81675
Contact: Claudia Regenbogen, MD    +49-089-4140-5644    Claudia.Regenbogen@mri.tum.de   
Principal Investigator: Claudia Regenbogen, MD         
Albrecht-Kossel-Institut für Neuroregeneration (AKos) Recruiting
Rostock, Germany, D-18147
Contact: Arndt Rolfs, MD    +49 381 494 95 40    arndt.rolfs@med.uni-rostock.de   
Principal Investigator: Arndt Rolfs, MD         
Helios Klinikum Schwerin Recruiting
Schwerin, Germany, D-19055
Contact: CA Prof. Peter Clemens, MD    +49-385 5202660    Peter.clemens@helios-kliniken.de   
Principal Investigator: Peter Clemens, MD         
Universitätsklinikum Ulm Recruiting
Ulm, Germany, D-89075
Contact: Michael Leichsenring, MD    0731 - 500 57143    michael.leichsenring@uniklinik-ulm.de   
Principal Investigator: Prof. Michael Leichsenring, MD         
Praxis für Innere Medizin Withdrawn
Wallgau, Germany, D-82499
Sponsors and Collaborators
Shire
Investigators
Principal Investigator: Shire Study Physician Shire
  More Information

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01356537     History of Changes
Other Study ID Numbers: Shire/CS03
Study First Received: May 17, 2011
Last Updated: February 1, 2017

Additional relevant MeSH terms:
Gaucher Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on July 19, 2017